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Pharmacogenetics: 
the path to personalized 
prescribing
The fact that different patients may show dissimilar responses to 
the same drug, has been recognised for several years, and many 
variables, such as age, gender and body weight have been identified 
to contribute to this observation.  The last half century has seen 
a rise in research concerning a new variable – genetic variation 
– which has been recognised to offer a major contribution to this 
phenomenon.  Pharmacogenetics research has today established 
itself as an important arm of pharmacology, and has key applications 
in drug development and clinical therapeutics.  The advent of high 
throughput methodologies coupled with new data derived from 
the human genome sequencing project, has helped to powerfully 
mobilise the developmental pace of this research work, and to 
introduce the concept of genome-wide pharmacogenetic studies, or 
pharmacogenomics.  The eventual development of pharmacogenetic 
tests, able to identify patients who are most likely to adequately 
respond to specific therapies from those who are not, will be 
a landmark in the history of therapeutics, and coupled to the 
development of new drugs for specific pharmacogenetically-stratified 
patient populations, will provide a markedly enhanced toolkit for the 
optimization of the benefit-risk ratio in prescribing. 
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Introduction
Pharmacogenetics and 
pharmacogenomics are terms which 
are today soundly entrenched within 
pharmacological and pharmaceutical 
literature.  The term pharmacogenetics 
was used for the first time by Friedrich 
Vogel in 1991, who coined it to describe 
the influence of genetic factors on the 
response to drugs.  In the following years, 
the number of peer-reviewed scientific 
publications dealing with this area, started 
to show a steady rise, while the last 10 
years has suddenly seen an exponential 
increase.  This is a reflection of the 
research explosion which has recently been 
occurring in this area.   A cursory look at 
the Medical Subject Heading (MeSH) fields 
of the National Library of Medicine Pubmed 
database, which to-date indexes over 11 
million articles2 gives evidence to this 
(Fig. 1).  Rubin and his workgroup recently 
reported on their use of an automated 
system, based on an algorithm designed to 
specifically data-mine biomedical literature 
databases for pharmacogenetics knowledge 
in order to extract specific reference lists 
which are more focused to a specific topic, 
than manual Boolean operator-linked 
multiple field search methods can provide.2
This article will review the relevance of 
this research area, and its implications to 
pharmacological therapeutics.
Pharmacogenetics	and	pharmacogenomics
The advent of novel research 
technologies, allowing high throughput 
screening of large numbers of biomolecules 
has ushered us into the –omics era of new 
methodologies such as transcriptomics 
(the large-scale study of the cell 
transcriptosome), metabolomics (the 
large-scale study of metabolite profiles), 
proteomics (the large-scale study of 
proteins) and in 199, pharmacogenomics.3  
Unfortunately, throughout the recent past, 
pharmacogenomics has often been used 
interchangeably with pharmacogenetics, 
blurring the large-scale gene-study 
implications inferred by the former term.  
The Nuffield Council on Bioethics, UK, 
defines pharmacogenetics as “the study of 
the effects of genetic differences between 
individuals in their response to medicines” 
and pharmacogenomics as “the examination 
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of whole genomes or substantial numbers 
of genes in order, for example, to identify 
putative targets for medicines or to identify 
large-scale differences in the patterns of 
gene expression in response to chemical 
compounds.” The National Centre for 
Biotechnology Information (NCBI), USA, 
uses a similar distinction between the 
terms and defines pharmacogenetics as “the 
study of inherited differences (variation) 
in drug metabolism and response” and 
pharmacogenomics as “the general study 
of all of the many different genes that 
determine drug behaviour.”  Table 1 lists 
various definitions as given by different 
official bodies, and it is evident, that even 
now, the distinction between both terms 
is not completely exclusive. Indeed, the 
International Union of Basic and Clinical 
Pharmacology (IUPHAR) states that “...there 
is no internationally accepted consensus 
depicting any semantic differences between 
pharmacogenetics and pharmacogenomics.”8 
However, while pharmacogenetics has been 
with us since Vogel’s first use of the term, 
pharmacogenomic research is mainly the 
fruit of the post-human genome sequencing 
era.
Pharmacogenetically-influenced	
drug	responses
Inter-individual variations in drug 
responses may be influenced by a plethora 
of variables.  These factors do not only 
influence therapeutic drug responses such 
as the degrees of efficacy and potency, 
but also the propensity to develop specific 
adverse effects.  Some of these variables 
such as age, gender and body weight are 
well known, and are regularly factored 
into algorithms used for drug dosing.  
Pharmacogenetic profiling fills in the gap 
for another variable, and its relevance 
is particularly accentuated in those 
instances where it is a primary factor in 
influencing patient-to-patient variability.  
In its simplest form, pharmacogenetic 
data may be used to identify patients in 
whom a drug shows adequate efficacy, 
from patients in whom the same drug 
does not.  This information may be used 
to assist the selection of which drug 
to administer to which patient, and to 
establish a relevant dosing schedule; in 
other words, to administer the right drug 
to the right patient at the right dose.   
Table 2 shows a sample list of genes for 
which specific variants have been shown 
to exert an influence on particular drug 
responses.  Changes in drug responses 
may be influenced by one particular 
genetic polymorphism alone, but more 
commonly, pharmacogenetically-influenced 
variations are the result of several gene 
variants interacting together and also with 
environmental factors, and this is one of 
the major challenges faced by researchers 
today.11,12
Adverse drug reactions (ADRs) are 
estimated to be responsible for up to 7% 
of hospital admissions in the UK, with an 
estimated annual direct cost amounting 
to EUR 00 million.13-1  In addition, 10% 
of drugs which had been approved by the 
FDA between 197 and 1999 were removed 
from the US market due to the appearance 
of new ADRs which were identified during 
the post-marketing surveillance stage.  
Besides known factors such as age, renal 
and liver function, disease status and 
lifestyle variables such as tobacco and 
alcohol consumption, genetic factors are 
also recognised to significantly modify 
the risk for development of ADRs.16  The 
classical example consists of genetic 
variation which decreases the activity of 
a drug metabolizing enzyme, resulting 
in a “slow-metabolizer” phenotype for a 
particular drug or group of drugs.  Such 
patients exhibit higher blood concentrations 
when administered the drug at conventional 
doses, since they take longer to metabolize 
it, often resulting in gradual accumulation 
to toxic levels.  Primary amongst the 
enzyme systems which have been studied 
in this respect, are the cytochrome P0 
(CYP) group, of which there are more 
than 30 gene families in humans.  One of 
the most studied CYP enzymes is CYP2D6 
which is responsible for the metabolism of 
more than 100 drugs, which derive from 
diverse pharmacological groups. Examples 
of these include propranolol, flecainide, 
amitriptyline, nortriptyline, clomipramine, 
fluoxetine, haloperidol, thioridazine, 
codeine, debrisoquine, dextromethorphan, 
phenformin and tramadol.  The CYP2D6 
gene exhibits significant variability, and 
more than 7 alleles have been identified 
to date.17 Some of these produce an enzyme 
with normal activity, some alleles produce 
an enzyme with high activity and some 
Figure	1:	The	number	of	publications	retrieved	using	a	Pubmed	search	
	 (http://www.pubmed.gov)	for	the	terms	“pharmacogenetics	
	 OR	pharmacogenomics”	in	the	MeSH	field.		The	data	shown	is	cumulative,
	 at	intervals	of	1	decade,	and	highlights	the	explosion	in	research
	 publications	which	occurred	since	the	start	of	this	millennium.
	 (MeSH:	Medical	Subject	Headings)
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produce a low-activity CYP2D6 enzyme.  In 
addition, individuals with multiple copies 
of functional CYP2D6 genes have been 
described, with resultant high enzyme 
expression and high CYP2D6 metabolic 
activity.  Patients may be classified as poor, 
normal, rapid or ultrarapid metabolisers 
with respect to CYP2D6 metabolic activity, 
and this may have significant clinical 
implications.  For example, the doses 
of nortriptyline required to attain a 
therapeutic response, may vary by over 
20-fold between poor and ultrarapid CYP2D6 
metabolizers.  If poor metabolisers are 
administered “normal” doses, they are 
more likely to develop ADRs due to slow 
elimination with consequential potential 
accumulation, while conversely, ultrarapid 
metabolisers may not show any therapeutic 
response at all.18 
Other pharmacogenetically-related ADRs 
may be related to membrane transporter 
proteins.    The Adenosine triphosphate-
Binding Cassette (ABC) genes code for 
a number of transmembrane proteins 
which are responsible for translocating 
drugs across extra- and intracellular 
cell membranes.  Examples of such 
drugs include anticancer drugs, digoxin, 
immunosuppressants and some antiretroviral 
agents.  Digoxin bioavailability, for example, 
is known to be influenced by variants of the 
ABCB1 gene.19 
Drug hypersensitivity may also be 
influenced by pharmacogenetic variation.  
For example, abacavir, an anti-retroviral 
drug used in the management of HIV 
infection, exhibits a five-fold greater risk of 
hypersensitivity in patients with the HLA-
B*701 allele, and some medical centres 
in the USA are today HLA-typing patients 
before prescribing the drug.20 
Personalized	medicine	
and	drug	development
The ultimate goal of pharmacogenetics 
and pharmacogenomics research is to enable 
prescribers to utilize a patient’s genetic 
data (pharmacogenetic profile) in order to 
enable the selection of the drug from the 
applicable therapeutic repertoire, which 
would exhibit the greatest efficacy and 
the least adverse effects in that particular 
patient, and the prescription of that drug at 
a dose that is appropriate for that patient; 
that is, genotype-guided prescribing, or 
as it has been more universally termed, 
personalized medicine.20  This goal, although 
often considered by the practitioner 
community to still be a distant vision, 
is advancing rapidly, and pharmaceutical 
companies are today already integrating 
pharmacogenomic aspects into the drug 
development process. 
This integration raises issues of a 
commercial interest.  The “niching” of 
drugs to selected genetic groups may 
restrict their potential markets, and may 
appear to disadvantage pharmaceutical 
companies.  However, the identification, 
during drug development, of a genetically-
determined target population in which the 
drug offers superior benefit than currently 
available medication, may potentially rescue 
an otherwise unmarketable drug into a 
marketable one.  Additionally, phase III 
trials of such a drug, may fail to indicate its 
superiority, unless they are performed in a 
genetically-selected population.21 
For what drugs may personalized 
medicine be expected to be available first?  
Several variables may influence this, but the 
following may offer some insight: 
a) drugs which show a high inter-individual 
variation in efficacy and/or potency.
b) drugs which possess a narrow therapeutic 
window and have to be used in 
conjunction with therapeutic drug 
monitoring.  Both the starting dose, as 
well as subsequent dosage adjustments 
may be made with greater accuracy, if 
the patient’s pharmacogenetic profile is 
included into the equation.
c)  drugs which demonstrate a clinical 
effect only several days after initiation 
of administration. The risk of having 
to substitute such a prescribed drug 
for another due to ineffective clinical 
outcome, or of having to alter the dose 
of the same drug, several days after 
therapy has been initiated, may be 
Nuffield	Council	on	Bioethics,	UK4	
Pharmacogenetics The study of the effects of genetic differences between individuals 
in their response to medicines.
Pharmacogenomics The examination of whole genomes or substantial numbers of genes 
in order, for example, to identify putative targets for medicines 
or to identify large-scale differences in the patterns of gene 
expression in response to chemical compounds.
The	National	Centre	for	Biotechnology	Information	(NCBI),	USA5	
Pharmacogenetics The study of inherited differences (variation) in drug metabolism 
and response.
Pharmacogenomics The general study of all of the many different genes that determine 
drug behaviour.
Food	and	Drug	Administration	(FDA),	USA6	
Pharmacogenetics The influence of variations in DNA sequence on drug response
Pharmacogenomics The investigation of variations of DNA and RNA characteristics as 
related to drug response.
 
European	Medicines	Agency	(EMEA),	UK7	
Pharmacogenetics The study of interindividual variations in DNA sequence related to 
drug response.
Pharmacogenomics The study of the variability of the expression of individual genes 
relevant to disease susceptibility as well as drug response at 
cellular, tissue, individual or population level. The term is broadly 
applicable to drug design, discovery, and clinical development.
 
International	Union	of	Basic	and	Clinical	Pharmacology	(IUPHAR),	USA8	
Pharmacogenetics The science about how heritability affects the response to drugs.
Pharmacogenomics How the systematic identification of all the human genes, their 
products, interindividual variation, intraindividual variation in 
expression and function over time may be used both to predict the 
right treatment in individual patients and to design new drugs.
Table	1:	 The	terms	pharmacogenetics	and	pharmacogenomics
	 as	defined	by	different	official	organisations
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minimized if the genetic influence on 
the efficacy and dose-requirement of the 
drug can be predicted for a particular 
patient.  This is especially important in 
diseases where optimum therapy has to 
be instituted as early as possible in order 
to optimize clinical prognosis.
d) drugs which are known to have the 
propensity to exhibit serious adverse 
effects, even if the incidence of such 
effects is low.
Regulatory	issues
Currently both the Food and Drug 
Administration (FDA), as well as the 
European Medicines Agency (EMEA) 
regulations do not require pharmacogenetic 
data to be submitted as part of a new 
drug licensing application.  However, the 
FDA is asking pharmaceutical companies 
conducting drug development programs to 
consider providing pharmacogenomic data 
to the Agency on a voluntary basis.  In this 
respect, the FDA has recently established 
an Interdisciplinary Pharmacogenomic 
Review Group (IPRG) to review voluntary 
pharmacogenomic data submissions (VGDSs) 
and provide feedback to submitters, 
provide guidance to the relevant FDA 
reviewing divisions and work on ongoing 
pharmacogenomic data submission policy 
development.22
At the same time, the EMEA Committee 
for Medicinal Products for Human Use 
(CHMP) established the Pharmacogenetics 
Working Party (PgWP), which currently 
meets four times a year in London and of 
which Malta is currently a member.  The 
primary PgWP’s mandate is to provide for 
a technical multidisciplinary forum to the 
CHMP pharmacogenetics experts network 
and applicants. It accomplishes this by 
hosting workshops and briefing meetings 
to share experience on pharmacogenetics-
related issues, preparing, reviewing and 
updating guidelines for the preparation and 
assessment of the pharmacogenetics parts 
of regulatory submissions, providing advice 
to the CHMP on general and product-specific 
matters relating to pharmacogenetics 
and liaising with interested parties and 
providing advice, through the CHMP, to the 
European Commission on pharmacogenetics-
related issues.23  Since their inception, 
The PgWP and the IPRG have established 
collaborative links between themselves, 
and have already had the opportunities 
to provide joint advice to pharmaceutical 
companies.
Interpretation	and	ethical	aspects
The concept of pharmacogenetic testing 
carries significant ethical implications.  
Issues which may be affected include the 
design of research studies and clinical 
trials, the pricing of medicines, and 
the accessibility of pharmacogenetic 
information by third parties.2  In 2003, 
the Nuffield Council on Bioethics, London, 
published a 132-page document which 
identified and presented issues relating 
to the correct use and interpretation of 
pharmacogenetic information and the 
implications of population stratification 
based on this data.  The following 
highlights some of the main issues 
discussed in this document.
Development of new medicines
The report encourages regulators 
to promote the collection and storage 
of samples derived from clinical trials 
such that they could be subjected to 
pharmacogenetic analysis either during 
the trial, or later.  This approach could 
permit re-analysis of data based on 
pharmacogenetic profile stratification, 
Gene	 Drug	affected	 Effect	  
CYP2C9  warfarin Increased anticoagulant effects 
  of warfarin 
 tolbutamide Hypoglycemia 
 phenytoin Toxicity 
CYP2C19  Omeprazole Peptic ulcer response to omeprazole 
 Diazepam  Prolonged sedation, toxicity 
CYP2D6  Nortriptyline, fluoxetine Increased antidepressant toxicity
 codeine Decreased codeine analgesia 
CYP3A/3A/3A7  tacrolimus Decreased efficacy of tacrolimus 
  in organ transplantation 
Dihydropyrimidine  Fluorouracil  Increased neurotoxicity 
dehydrogenase  
Glutathione transferase Several anticancer  Increased response in breast cancer, 
GSTM1, M3, T1 agents more toxicity and poorer outcome in
  acute myeloid leukaemia  
Thiopurine  Mercaptopurine,   Increased haematopoietic toxicity
methyltransferase thioguanine, 
 azathioprine
UGT1A1  Irinotecan  Increased gastrointestinal toxicity 
ABCB1 (MDR-1)  Digoxin,  Decreased digoxin bioavailability 
 HIV protease inhibitors Decreased CD response 
  in HIV-infected patients, 
ß2-adrenoceptor  ß2-adrenergic agonists  Decreased bronchodilation response
 (eg. salbutamol, 
 terbutaline)   
ß1-adrenoceptor  ß1-adrenergic  Decreased cardiovascular response 
 antagonists
Gsα subunit ß1-adrenergic  Decreased antihypertensive effect 
 antagonists 
ALOX  Leukotriene receptor  Less improvement in FEV1 
 antagonists (forced expiratory volume in 1 second) 
Serotonin transporter  fluoxetine and other  Decreased antidepressant response
(-HTT) anti-depressants  
Human leukocyte  Abacavir  Increased liklihood 
antigen (HLA)  of hypersensitivity 
N-Acetyl-transferase 2  Isoniazid  Exaggerated drug response, 
(NAT2)  toxic metabolites  
Sulfonylurea receptor  Tolbutamide  Decreased insulin response 
Table	2:	 A	non-exhaustive	list	of	genes	for	which	specific	variants	have	
	 been	shown	to	have	clinical	implications	for	specific	pharmacological
	 therapies.		This	list	has	been	compiled	from	reviews	by	Frueh	and	Gurwitz
	 (2004),9	and	Evans	and	Relling	(2004).10	
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and could identify smaller groups in whom 
the trial results are more robust, and who 
would be better candidates for the medicine 
being tested.  The issue of population 
stratification presents as a double-edged 
blade in terms of commercial development.  
Some potentially valuable new medicines 
may not be developed if, as a result of 
genetic stratification, the number of 
patients who would benefit is too small 
for the venture to be commercially viable. 
However, stratification may also enable 
some medicines to be developed that would 
otherwise have failed because the subgroup 
in which the medicine is effective can now 
be distinguished.
Improvement of existing medicines
Pharmacogenetics could be used 
to improve the prescribing of existing 
medicines, for example either by predicting 
individualized dosing and thus reducing 
the incidence of adverse reactions, or by 
restricting prescription to those patients 
likely to benefit. Some potential examples 
include clozapine and warfarin for which 
sufficient data exists to make these 
strong candidates.  The Nuffield Council 
recommended that efforts should be made 
to encourage pharmacogenetic research 
on existing medicines, where there is 
reason to believe that such research could 
significantly improve efficacy or safety, 
and that funding and support should be 
made available within the public sector 
and public–private partnerships should be 
encouraged.
Withdrawn medicines
The most common reason for medicines 
to be withdrawn from the market once 
they have been licensed is the subsequent 
occurrence of serious adverse reactions, 
which were either unsuspected at the time 
of marketing authorisation or occur more 
frequently than was expected.  If some 
adverse reactions can be explained by 
genetic variation, pharmacogenetic analysis 
might enable some withdrawn medicines to 
be reinstated, by restricting their licensed 
used to a genetically-defined group of 
patients.  This may be especially relevant in 
cases where there is currently no alternative 
treatment available to replace a withdrawn 
medicine.
Cost
The incorporation of pharmacogenetic 
studies in drug development, would be 
likely to influence the cost of the final 
product.  This has pharmacoeconomic 
implications and might adversely influence 
cost-benefit issues, possibly also presenting 
a barrier to medicine access.
Information, training and education
The results of a pharmacogenetic 
test may not be as easily interpretable as 
other clinical tests, and the way in which 
the data may be best used, may not be 
immediately evident.  In a number of 
instances, pharmacogenetic tests will not 
draw a clear line between a patient being 
a responder / non-responder to a particular 
drug, but will rather predict the likelihood 
of that’s patient’s response.  The prescriber 
may have to consider other factors besides 
pharmacogenetic data, while taking a 
decision, especially when bringing dosage 
regimen into the equation.   Adequate 
training must be provided for clinicians and 
pharmacists to enable them to interpret 
such pharmacogenetic tests correctly and 
to advise patients accordingly. The Nuffield 
Council recommended that such testing 
should not be made available directly to 
the patient but only to trained health care 
professionals.  However, in the case of 
pharmacogenetic tests which are able to 
provide a clear cut responder/non-responder 
result, patients could be provided with 
the means to directly request such testing 
themselves.  The selection of tests which 
could be made available in this way should 
be decided by the relevant Health Authority.
Ethnicity
Particular genetic variation may often 
be clustered to specific ethnic populations.  
Although ethnicity alone should not be used 
as a replacement for a pharmacogenetic 
test, this situation could make the 
commercialization of some drugs only viable 
within certain ethnic groups.  This could 
cause serious concerns where, for example, 
solely due to commercial interests, whole 
countries could be denied the availability 
of these drugs, even though specific 
individuals may test pharmacogenetically 
positive for their use.
Drug licensing
Even if it will improve the likelihood of 
receiving a safe and effective treatment, 
some patients might have an aversion to 
taking a pharmacogenetic test, either, 
for example because it might become 
more difficult to obtain health insurance, 
• The major aim of pharmacogenetic and pharmacogenomic research is to enable 
prescribers to administer the right drug to the right patient at the right dose, i.e. to 
enable the establishment of personalized medicine.
• Dugs which are strong candidates are those which (a) show high inter-patient 
variability, (b) have a narrow therapeutic window, (c) demonstrate a clinical effect 
several days after initiation of administration, and/or (d) may exhibit serious 
adverse reactions.
• FDA and EMEA do not mandate pharmacogenetic data submissions as part of a new 
drug licensing application, but both organisations recommend it and both have 
established expert committees to evaluate this data.
• In drug development, pharmacogenetic research may aid in the development of new 
medicines for specific genetically-defined groups, it may improve existing medicines 
by identifying the patients in whom they show the highest benefit and it may re-
instate some withdrawn medicines by restricting their licensed use to a genetically-
defined subgroup of patients. 
• For some drugs, pharmacogenetic tests will not unequivocally delineate patients 
who would and would not benefit from their use, but would rather predict the 
likelihood of each patient’s response. Adequate training must be provided for 
clinicians and pharmacists to enable them to correctly interpret such tests and 
advise patients accordingly.
Key	Points
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or because it might indirectly reveal 
information about a medical condition 
which cannot be effectively treated.  A 
question arises regarding whether these 
patients will still have the option to receive 
treatment without taking an associated test, 
or whether the drug licensing conditions 
will mandate it.  This may also be relevant 
in developing countries which do not have 
recourse to testing, thus effectively making 
any use of such a drug in these countries, 
fall under off-label prescribing.
Use by insurers
Pharmacogenetic information could 
be of relevance to insuring companies, 
especially those providing types of 
healthcare insurance such as private medical 
insurance and long-term care insurance, 
as well as life insurers.  Such genotyping 
may be used to classify individuals as 
“more expensive” or “less expensive” to 
treat and could be used to define premiums 
for people applying for policies, as well 
as to adjudicate claims in order to make 
decisions about payment to policy-holders.  
The Nuffield Council strongly advocates in 
favour of the setting up of regulations that 
would deny insurers any right to request 
genetic information.
Conclusion
Half a century from the Watson and 
Crick’s identification of DNA structure, and 
 years from the completion of the Human 
Genome Sequence, the implications of 
genetic research have infiltrated our daily 
lives.  Pharmacogenetic-based individualized 
drug therapy aims to provide a safer 
and personalized therapeutic option for 
patients, with better clinical outcomes and 
disease prognosis.  As new high throughput 
research methodologies are developed, 
and further automation is introduced into 
research laboratories, the development 
and commercialization of pharmacogenetic 
tests may become a reality sooner rather 
than later.  Roses, in 20022 had already 
speculated that a pharmacogenetic test kit 
could be developed by a pharmaceutical 
company, validated and commercialized 
within a time frame as short as 2 to 3 
years, and more recently, Lesko (2007)12 
suggested that a pharmacogenetic kit 
could be commercialized for point-of-care 
use by the prescriber himself at a cost of 
only around USD0 per test.  Now is the 
time for health care professionals to start 
seeking the knowledge and training that 
will prepare them for the introduction 
of pharmacogenetics/pharmacogenomics 
into the framework of pharmacological 
management and patient care.
